Search

Articles

Articles

Man, Struggling to Match Son’s Air Force Fitness Requirements, Discovers He Has a Rare and Serious Blood Disorder (Exclusive)

“It was very humbling and scarier than any horror movie,” Michael...

DeKalb County woman beats rare disease after 30-year medical journey

Tanya became one of the first patients in the United States...

Safety and efficacy data from Nexicart-2, the first US trial of CAR-T in R/R light chain (AL) amyloidosis, Nxc-201

7508Background: No FDA approved treatments exist for relapsed/refractory (RR) AL Amyloidosis....

First 20-patient safety and efficacy data from nexicart-2, the first u.S. trial of CAR-T in R/R light chain (AL) amyloidosis, nxc-201 | Blood | American Society of Hematology

AbstractBackground: No FDA approved treatments exist for relapsed/refractory (RR) AL Amyloidosis....

First 23-Patient Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of CAR-T in R/R Light Chain (AL) Amyloidosis, Nxc-201

No FDA approved drugs exist for relapsed/refractory (RR) AL Amyloidosis. CAR-T...

FDA

NXC-201 Earns FDA RMAT Designation in AL Amyloidosis

The FDA granted Regenerative Medicine Advanced Therapy designation to NXC-201 for...

ASH 2023 | Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis

Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses...

Dr Raza on Early Safety and Efficacy Data With NXC-201 in AL Amyloidosis

Shahzad Raza, MD, shares preliminary data from the NEXICART-2 trial of...